Biotech Values

[microcapfun]

Comments on ... Human Genome Sciences Announces Positive Final Results of Phase 2b Trial of Albuferon

Dew said: Clinical results are not automatically positive just because a PR says so, and I would characterize these data as middling.

Yeah. And compared to the previous update, they suck.

To summarize, at 12 weeks post treatment, SVR12 rates for Albuferon minus Pegasys were
5%, 2% and -1%.
But at 24 weeks post treatment (which as you say is the only thing that counts) SVR rates were
0.6%, -2.4% and -7.0%.

Yechh. The key is that SVR for the Pegasys arm actually went up w/o treatment, from 54% to 57.9%! I wonder how that happened.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_H/threadview?m=tm&bn=8514&tid=6...

(If interested, read the entire Yahoo thread for context.)

micro